Cargando…
Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition
EZH2 inhibitors have gained great interest for their use as anti-cancer therapeutics. However, most research has focused on EZH2 mutant cancers and recently adverse effects of EZH2 inactivation have come to light. To determine whether colorectal cancer cells respond to EZH2 inhibition and to explore...
Autores principales: | Koppens, Martijn AJ, Bounova, Gergana, Cornelissen-Steijger, Paulien, de Vries, Nienke, Sansom, Owen J, Wessels, Lodewyk FA, van Lohuizen, Maarten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342517/ https://www.ncbi.nlm.nih.gov/pubmed/27634879 http://dx.doi.org/10.18632/oncotarget.12002 |
Ejemplares similares
-
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
por: Pietersen, Alexandra M, et al.
Publicado: (2008) -
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
por: Puppe, Julian, et al.
Publicado: (2009) -
Applications of DNA integrating elements: Facing the bias bully
por: de Jong, Johann, et al.
Publicado: (2015) -
GFAP-Cre-Mediated Transgenic Activation of Bmi1 Results in Pituitary Tumors
por: Westerman, Bart A., et al.
Publicado: (2012) -
Multiplexed Cas9 targeting reveals genomic location effects and gRNA-based staggered breaks influencing mutation efficiency
por: Gisler, Santiago, et al.
Publicado: (2019)